ClinicalTrials.gg
CompletedNCT02558296BESTUpdated Jul 14, 2021Results posted

Bexagliflozin Efficacy and Safety Trial

A Phase 3 interventional study of Bexagliflozin and Placebo in Type 2 Diabetes Mellitus, sponsored by Theracos. Completed at 157 sites in 10 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2021-07-14.

Sponsored by Theracos · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,700
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 15 studies testing bexagliflozin in Diabetes Mellitus, Type 2 — 1 open to participants now, 1 under way, none of them phase 3. Bexagliflozin · Diabetes Mellitus, Type 2.

Enrollment
Largest of 15
1,700 · median 64
Started
2015
with 1 other
Phase 3
5 of 15
none open now
Registered
3rd of 15
by date
Lead sponsor
13 of 15
Theracos

Among the 15 studies testing bexagliflozin in Diabetes Mellitus, Type 2, this one has the largest enrollment, is one of 2 that started in 2015, is one of 5 in phase 3, and was the 3rd registered.

Diabetes Mellitus, Type 2

10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

1 of the 15 studies testing bexagliflozin in Diabetes Mellitus, Type 2 is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About bexagliflozin

Bexagliflozin: first FDA approval 2023 (BRENZAVVY). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies testing bexagliflozin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

The purpose of this study is to investigate the effect of bexagliflozin in lowering hemoglobin A1c (HbA1c) levels in patients with type 2 diabetes mellitus (T2DM) and increased risk of cardiovascular adverse events.

The data from this study will be combined with the data from other bexagliflozin studies in a meta-analysis of CV safety outcomes.

Read the detailed description

Approximately 130 investigative sites globally are planned to participate in this study.

An estimated 1650 subjects with inadequately controlled T2DM and an elevated risk of cardiovascular adverse events will be randomized to bexagliflozin tablets, 20 mg, or placebo in a ratio of 2:1 in addition to the background anti-diabetic medications.

The study is an event-driven trial. The treatment period will end when the last randomized subject has completed at least 52 weeks of treatment and a total of at least 134 subjects have experienced a cardiac event.

03

Conditions studied

  • Type 2 Diabetes Mellitus
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects with a diagnosis of T2DM
  • Subjects who have had a stable treatment regimen for T2DM for the past 3 months
  • Subjects who present with at least one of the following 3 histories:

Group 1: A history of atherosclerotic vascular disease Group 2: A history of heart failure Group 3: Age ≥ 55 years with diabetes for ≥ 10 years, uncontrolled hypertension, currently smoking, reduced kidney function, or cholesterol problems

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of type 1 diabetes mellitus or maturity-onset/diabetes of the young
  • History of genitourinary tract infections
  • Evidence of abnormal liver function
  • History of MI, stroke or hospitalization for heart failure in the past 3 months
  • Prior kidney transplant or evidence of kidney problems
  • Prior or planned pace maker implantation
  • Pregnant or nursing
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,700 participants (actual)

Study arms

  • Active comparator
    Bexagliflozin tablets, 20 mg

    Each subject will receive bexagliflozin 20 mg once daily for the duration of the study.

    Drug: Bexagliflozin

  • Placebo comparator
    Placebo tablets

    Each subject will receive placebo (inactive tablet) once daily for the duration of the study.

    Drug: Placebo

Interventions

  • 20 mg, tablet

    Also known as: EGT0001442, EGT0001474

  • DrugPlacebo

    20 mg tablet to match active comparator

06

What researchers measure

Primary outcomes

  1. Change in HbA1c From Baseline to Week 24

    The primary efficacy objective of this trial is to evaluate the placebo-adjusted change in HbA1c from baseline after 24 weeks of treatment with 20 mg bexagliflozin tablets in type 2 diabetic subjects with increased risk of cardiovascular adverse events.

    Time frame: 24 weeks

Secondary outcomes

  1. Change From Baseline in HbA1c at Week 24 for Subjects Who Have Been Prescribed Insulin

    To evaluate the effect of 20 mg bexagliflozin on the change in HbA1c from baseline to week 24 in randomized subjects who have been prescribed insulin to control their diabetes

    Time frame: 24 weeks

  2. Change in Body Weight From Baseline to Week 48

    To evaluate the effect of 20 mg bexagliflozin on the change in body weight from baseline to week 48 in randomized subjects with a BMI ≥ 25 kg/m2 compared to placebo

    Time frame: 48 weeks

  3. Change in Systolic Blood Pressure From Baseline to Week 24 in Subjects Hypertensive at Baseline

    To evaluate the effect of 20 mg bexagliflozin on the change in systolic blood pressure (SBP) from baseline to week 24 in subjects with baseline systolic blood pressure ≥ 140 mmHg compared to placebo

    Time frame: 24 weeks

Other outcomes

  1. Change in HbA1c From Baseline Over Time

    To assess the effect of 20 mg bexagliflozin treatment on the change in HbA1c from baseline versus placebo over time up to 168 weeks

    Time frame: Baseline (week 0) and weeks 6, 12, 24, 36, 48, 72, 96, 120, 144 and 168

  2. Change in Fasting Plasma Glucose Over Time

    To evaluate the effect of bexagliflozin treatment on the change in fasting plasma glucose (FPG) versus placebo over time up to 168 weeks

    Time frame: Baseline (week 0) and weeks 6, 12, 24, 36, 48, 72, 96, 120, 144 and 168

  3. Proportion of Subjects Requiring an Intensification of Hypoglycemic Agent and Time to First Intensification

    To measure the proportion of subjects requiring an intensification of hypoglycemic agent in the bexagliflozin arm versus placebo during 24 week period

    Time frame: 24 week

  4. Proportion of Subjects Requiring an Intensification of Hypoglycemic Agent and Time to First Intensification

    To measure the proportion of subjects requiring an intensification of hypoglycemic agent in the bexagliflozin arm versus placebo during the entire study period

    Time frame: Duration of study (168 weeks)

  5. Proportion of Subjects Requiring a Relaxation of Hypoglycemic Agent

    To measure the proportion of subjects requiring a relaxation of hypoglycemic agent in the bexagliflozin arm versus placebo during 24 week period

    Time frame: 24 weeks

  6. Proportion of Subjects Requiring a Relaxation of Hypoglycemic Agent

    To measure the proportion of subjects requiring a relaxation of hypoglycemic agent in the bexagliflozin arm versus placebo during the entire study

    Time frame: Duration of study (168 weeks)

  7. Proportion of Participants With Incidence of Hospitalization for Heart Failure

    To measure the incidence of hospitalization for heart failure among all subjects and among subjects who have a history of heart failure at baseline

    Time frame: Duration of study (168 weeks)

07

Results

Posted Jul 7, 2021

Participant flow

A total of 1700 patients were recruited from 10 countries: Canada, Czech Republic, Demark, Republic of Korea, Mexico, the Netherlands, Poland, Russian Federation, Taiwan, and the United States.

Completed the Study Through Week 24
Participant flow — Completed the Study Through Week 24
MilestoneBexagliflozin Tablets, 20 mgPlacebo Tablets
Started1133567
Completed1089542
Not completed4425
Withdrew: Adverse event93
Withdrew: Death77
Withdrew: Lost to follow-up81
Withdrew: Physician decision10
Withdrew: Protocol violation11
Withdrew: Withdrawal by subject1713
Withdrew: The subject was randomized, but did not take any investigational product10
Completed the Study
Participant flow — Completed the Study
MilestoneBexagliflozin Tablets, 20 mgPlacebo Tablets
Started1133567
Completed987482
Not completed14685
Withdrew: Adverse event145
Withdrew: Death3925
Withdrew: Lost to follow-up3123
Withdrew: Physician decision60
Withdrew: Protocol violation21
Withdrew: Withdrawal by subject5331
Withdrew: The subject was randomized, but did not take any investigational product10

Outcome measures

PrimaryChange in HbA1c From Baseline to Week 24

The primary efficacy objective of this trial is to evaluate the placebo-adjusted change in HbA1c from baseline after 24 weeks of treatment with 20 mg bexagliflozin tablets in type 2 diabetic subjects with increased risk of cardiovascular adverse events.

Time frame:
24 weeks
Reported as:
Least squares mean · percentage of glycated hemoglobin
Change in HbA1c From Baseline to Week 24
percentage of glycated hemoglobinBexagliflozin Tablets, 20 mgPlacebo Tablets
Change in HbA1c From Baseline to Week 24-0.85 (-0.90 to -0.80)-0.37 (-0.44 to -0.30)
Statistical analysis
  • Bexagliflozin Tablets, 20 mg vs Placebo Tablets · Mixed-effects repeated measures · p = <0.0001 (P-value is based on one sided statistical tests using a 0.025 level of significance.) · Mean difference (net): -0.48 · 95% CI -0.56 to -0.39Region, baseline eGFR categories and BMI, history of heart failure, insulin use (Y/N), treatment, visit and baseline HbA1c as fixed effect covariate.
SecondaryChange From Baseline in HbA1c at Week 24 for Subjects Who Have Been Prescribed Insulin

To evaluate the effect of 20 mg bexagliflozin on the change in HbA1c from baseline to week 24 in randomized subjects who have been prescribed insulin to control their diabetes

Time frame:
24 weeks
Reported as:
Least squares mean · Percentage of HbA1c
Change From Baseline in HbA1c at Week 24 for Subjects Who Have Been Prescribed Insulin
Percentage of HbA1cBexagliflozin Tablets, 20 mgPlacebo Tablets
Change From Baseline in HbA1c at Week 24 for Subjects Who Have Been Prescribed Insulin-0.84 (-0.92 to -0.77)-0.32 (-0.43 to -0.22)
Statistical analysis
  • Bexagliflozin Tablets, 20 mg vs Placebo Tablets · Mixed-effects repeated measures · p = <0.0001 (P-value is based on one sided statistical tests using a 0.025 level of significance.) · Mean difference (net): -0.52 · 95% CI -0.65 to -0.40Region, baseline eGFR categories, history of heart failure, treatment, visit and baseline HbA1c as fixed effect covariate.
SecondaryChange in Body Weight From Baseline to Week 48

To evaluate the effect of 20 mg bexagliflozin on the change in body weight from baseline to week 48 in randomized subjects with a BMI ≥ 25 kg/m2 compared to placebo

Time frame:
48 weeks
Reported as:
Least squares mean · kg
Change in Body Weight From Baseline to Week 48
kgBexagliflozin Tablets, 20 mgPlacebo Tablets
Change in Body Weight From Baseline to Week 48-3.03 (-3.27 to -2.80)-0.38 (-0.72 to -0.04)
Statistical analysis
  • Bexagliflozin Tablets, 20 mg vs Placebo Tablets · Mixed-effects repeated measures · p = <0.0001 (P-value is presented based on one-sided statistical tests using a 0.025 level of significance.) · Mean difference (net): -2.65 · 95% CI -3.07 to -2.24Region, baseline HbA1c and eGFR, history of heart failure, insulin use (Y/N), treatment, visit and baseline body weight as fixed effect covariate.
SecondaryChange in Systolic Blood Pressure From Baseline to Week 24 in Subjects Hypertensive at Baseline

To evaluate the effect of 20 mg bexagliflozin on the change in systolic blood pressure (SBP) from baseline to week 24 in subjects with baseline systolic blood pressure ≥ 140 mmHg compared to placebo

Time frame:
24 weeks
Reported as:
Least squares mean · mm Hg
Change in Systolic Blood Pressure From Baseline to Week 24 in Subjects Hypertensive at Baseline
mm HgBexagliflozin Tablets, 20 mgPlacebo Tablets
Change in Systolic Blood Pressure From Baseline to Week 24 in Subjects Hypertensive at Baseline-9.83 (-11.28 to -8.38)-6.87 (-8.95 to -4.78)
Statistical analysis
  • Bexagliflozin Tablets, 20 mg vs Placebo Tablets · Mixed-effects repeated measures · p = 0.0112 (P-value is presented based on one-sided statistical tests using a 0.025 level of significance.) · Mean difference (net): -2.96 · 95% CI -5.51 to -0.42Region, baseline HbA1c, GFR categories, BMI, history of heart failure, insulin use (Y/N), treatment, visit and baseline SBP as fixed effect covariate.
Other pre-specifiedChange in HbA1c From Baseline Over Time

To assess the effect of 20 mg bexagliflozin treatment on the change in HbA1c from baseline versus placebo over time up to 168 weeks

Time frame:
Baseline (week 0) and weeks 6, 12, 24, 36, 48, 72, 96, 120, 144 and 168
Reported as:
Least squares mean · Percentage of HbA1c
Change in HbA1c From Baseline Over Time
Percentage of HbA1cBexagliflozin Tablets, 20 mgPlacebo Tablets
Week 6-0.69 (-0.72 to -0.65)-0.24 (-0.28 to -0.19)
Week 12-0.89 (-0.94 to -0.85)-0.34 (-0.39 to -0.28)
Week 24-0.84 (-0.89 to -0.79)-0.37 (-0.45 to -0.30)
Week 36-0.86 (-0.92 to -0.81)-0.39 (-0.47 to -0.32)
Week 48-0.84 (-0.90 to -0.79)-0.38 (-0.46 to -0.30)
Week 72-0.76 (-0.83 to -0.70)-0.34 (-0.44 to -0.25)
Week 96-0.68 (-0.75 to -0.62)-0.29 (-0.39 to -0.20)
Week 120-0.65 (-0.73 to -0.58)-0.22 (-0.33 to -0.11)
Week 144-0.62 (-0.71 to -0.53)-0.23 (-0.37 to -0.10)
Week 168-0.56 (-0.67 to -0.45)-0.29 (-0.46 to -0.13)
Statistical analysis
  • Bexagliflozin Tablets, 20 mg vs Placebo Tablets · Mixed-effects repeated measures · p = <0.0001 (P-value is based on one sided statistical tests using a 0.025 level of significance.) · Mean difference (final values): -0.45 · 95% CI -0.50 to -0.39Region, baseline eGFR categories and BMI, history of heart failure, insulin use (Y/N), treatment, visit and baseline HbA1c as fixed effect covariate.
  • Bexagliflozin Tablets, 20 mg vs Placebo Tablets · Mixed-effects repeated measures · p = <0.0001 (P-value is based on one sided statistical tests using a 0.025 level of significance.) · Mean difference (final values): -0.56 · 95% CI -0.63 to -0.49Region, baseline eGFR categories and BMI, history of heart failure, insulin use (Y/N), treatment, visit and baseline HbA1c as fixed effect covariate.
  • Bexagliflozin Tablets, 20 mg vs Placebo Tablets · Mixed-effects repeated measures · p = <0.0001 (P-value is based on one sided statistical tests using a 0.025 level of significance.) · Mean difference (final values): -0.47 · 95% CI -0.56 to -0.38Region, baseline eGFR categories and BMI, history of heart failure, insulin use (Y/N), treatment, visit and baseline HbA1c as fixed effect covariate.
  • Bexagliflozin Tablets, 20 mg vs Placebo Tablets · Mixed-effects repeated measures · p = <0.0001 (P-value is based on one sided statistical tests using a 0.025 level of significance.) · Mean difference (final values): -0.47 · 95% CI -0.56 to -0.38Region, baseline eGFR categories and BMI, history of heart failure, insulin use (Y/N), treatment, visit and baseline HbA1c as fixed effect covariate.
  • Bexagliflozin Tablets, 20 mg vs Placebo Tablets · Mixed-effects repeated measures · p = <0.0001 (P-value is based on one sided statistical tests using a 0.025 level of significance.) · Mean difference (final values): -0.46 · 95% CI -0.56 to -0.37Region, baseline eGFR categories and BMI, history of heart failure, insulin use (Y/N), treatment, visit and baseline HbA1c as fixed effect covariate.
  • Bexagliflozin Tablets, 20 mg vs Placebo Tablets · Mixed-effects repeated measures · p = <0.0001 (P-value is based on one sided statistical tests using a 0.025 level of significance.) · Mean difference (final values): -0.42 · 95% CI -0.54 to -0.31Region, baseline eGFR categories and BMI, history of heart failure, insulin use (Y/N), treatment, visit and baseline HbA1c as fixed effect covariate.
  • Bexagliflozin Tablets, 20 mg vs Placebo Tablets · Mixed-effects repeated measures · p = <0.0001 (P-value is based on one sided statistical tests using a 0.025 level of significance.) · Mean difference (final values): -0.39 · 95% CI -0.51 to -0.27Region, baseline eGFR categories and BMI, history of heart failure, insulin use (Y/N), treatment, visit and baseline HbA1c as fixed effect covariate.
  • Bexagliflozin Tablets, 20 mg vs Placebo Tablets · Mixed-effects repeated measures · p = <0.0001 (P-value is based on one sided statistical tests using a 0.025 level of significance.) · Mean difference (final values): -0.43 · 95% CI -0.56 to -0.30Region, baseline eGFR categories and BMI, history of heart failure, insulin use (Y/N), treatment, visit and baseline HbA1c as fixed effect covariate.
  • Bexagliflozin Tablets, 20 mg vs Placebo Tablets · Mixed-effects repeated measures · p = <0.0001 (P-value is based on one sided statistical tests using a 0.025 level of significance.) · Mean difference (final values): -0.38 · 95% CI -0.54 to -0.23Region, baseline eGFR categories and BMI, history of heart failure, insulin use (Y/N), treatment, visit and baseline HbA1c as fixed effect covariate.
  • Bexagliflozin Tablets, 20 mg vs Placebo Tablets · Mixed-effects repeated measures · p = 0.0045 (P-value is based on one sided statistical tests using a 0.025 level of significance.) · Mean difference (final values): -0.27 · 95% CI -0.47 to -0.07Region, baseline eGFR categories and BMI, history of heart failure, insulin use (Y/N), treatment, visit and baseline HbA1c as fixed effect covariate.
Other pre-specifiedChange in Fasting Plasma Glucose Over Time

To evaluate the effect of bexagliflozin treatment on the change in fasting plasma glucose (FPG) versus placebo over time up to 168 weeks

Time frame:
Baseline (week 0) and weeks 6, 12, 24, 36, 48, 72, 96, 120, 144 and 168
Reported as:
Least squares mean · mmol/L
Change in Fasting Plasma Glucose Over Time
mmol/LBexagliflozin Tablets, 20 mgPlacebo Tablets
Week 6-1.28 (-1.40 to -1.16)0.07 (-0.10 to 0.24)
Week 12-1.33 (-1.46 to -1.21)0.06 (-0.12 to 0.23)
Week 24-1.43 (-1.56 to -1.30)-0.05 (-0.23 to 0.13)
Week 36-1.21 (-1.36 to -1.06)-0.06 (-0.27 to 0.15)
Week 48-1.36 (-1.50 to -1.21)-0.12 (-0.33 to 0.08)
Week 72-1.14 (-1.30 to -0.98)-0.15 (-0.38 to 0.07)
Week 96-1.16 (-1.32 to -0.99)0.04 (-0.20 to 0.29)
Week 120-0.90 (-1.09 to -0.71)0.25 (-0.02 to 0.53)
Week 144-1.03 (-1.24 to -0.81)-0.40 (-0.72 to -0.08)
Week 168-1.06 (-1.39 to -0.73)-0.55 (-1.04 to -0.07)
Statistical analysis
  • Bexagliflozin Tablets, 20 mg vs Placebo Tablets · Mixed-effects repeated measures · p = <0.0001 (P-value is based on one sided statistical tests using a 0.025 level of significance.) · Mean difference (final values): -1.35 · 95% CI -1.55 to -1.15Region, baseline eGFR categories \& BMI, history of HF, insulin use, treatment, visit, hypoglycemic use and baseline FPG as fixed effect covariate.
  • Bexagliflozin Tablets, 20 mg vs Placebo Tablets · Mixed-effects repeated measures · p = <0.0001 (P-value is based on one sided statistical tests using a 0.025 level of significance.) · Mean difference (final values): -1.39 · 95% CI -1.61 to -1.18Region, baseline eGFR categories \& BMI, history of HF, insulin use, treatment, visit, hypoglycemic use and baseline FPG as fixed effect covariate.
  • Bexagliflozin Tablets, 20 mg vs Placebo Tablets · Mixed-effects repeated measures · p = <0.0001 (P-value is based on one sided statistical tests using a 0.025 level of significance.) · Mean difference (final values): -1.39 · 95% CI -1.61 to -1.16Region, baseline eGFR categories \& BMI, history of HF, insulin use, treatment, visit, hypoglycemic use and baseline FPG as fixed effect covariate.
  • Bexagliflozin Tablets, 20 mg vs Placebo Tablets · Mixed-effects repeated measures · p = <0.0001 (P-value is based on one sided statistical tests using a 0.025 level of significance.) · Mean difference (final values): -1.15 · 95% CI -1.41 to -0.89Region, baseline eGFR categories \& BMI, history of HF, insulin use, treatment, visit, hypoglycemic use and baseline FPG as fixed effect covariate.
  • Bexagliflozin Tablets, 20 mg vs Placebo Tablets · Mixed-effects repeated measures · p = <0.0001 (P-value is based on one sided statistical tests using a 0.025 level of significance.) · Mean difference (final values): -1.23 · 95% CI -1.48 to -0.98Region, baseline eGFR categories \& BMI, history of HF, insulin use, treatment, visit, hypoglycemic use and baseline FPG as fixed effect covariate.
  • Bexagliflozin Tablets, 20 mg vs Placebo Tablets · Mixed-effects repeated measures · p = <0.0001 (P-value is based on one sided statistical tests using a 0.025 level of significance.) · Mean difference (final values): -0.99 · 95% CI -1.27 to -0.72Region, baseline eGFR categories \& BMI, history of HF, insulin use, treatment, visit, hypoglycemic use and baseline FPG as fixed effect covariate.
  • Bexagliflozin Tablets, 20 mg vs Placebo Tablets · Mixed-effects repeated measures · p = <0.0001 (P-value is based on one sided statistical tests using a 0.025 level of significance.) · Mean difference (final values): -1.20 · 95% CI -1.50 to -0.90Region, baseline eGFR categories \& BMI, history of HF, insulin use, treatment, visit, hypoglycemic use and baseline FPG as fixed effect covariate.
  • Bexagliflozin Tablets, 20 mg vs Placebo Tablets · Mixed-effects repeated measures · p = <0.0001 (P-value is based on one sided statistical tests using a 0.025 level of significance.) · Mean difference (final values): -1.15 · 95% CI -1.49 to -0.82Region, baseline eGFR categories \& BMI, history of HF, insulin use, treatment, visit, hypoglycemic use and baseline FPG as fixed effect covariate.
  • Bexagliflozin Tablets, 20 mg vs Placebo Tablets · Mixed-effects repeated measures · p = 0.0008 (P-value is based on one sided statistical tests using a 0.025 level of significance.) · Mean difference (final values): -0.63 · 95% CI -1.01 to -0.24Region, baseline eGFR categories \& BMI, history of HF, insulin use, treatment, visit, hypoglycemic use and baseline FPG as fixed effect covariate.
  • Bexagliflozin Tablets, 20 mg vs Placebo Tablets · Mixed-effects repeated measures · p = 0.0462 (P-value is based on one sided statistical tests using a 0.025 level of significance.) · Mean difference (final values): -0.50 · 95% CI -1.09 to 0.08Region, baseline eGFR categories \& BMI, history of HF, insulin use, treatment, visit, hypoglycemic use and baseline FPG as fixed effect covariate.
Other pre-specifiedProportion of Subjects Requiring an Intensification of Hypoglycemic Agent and Time to First Intensification

To measure the proportion of subjects requiring an intensification of hypoglycemic agent in the bexagliflozin arm versus placebo during 24 week period

Time frame:
24 week
Reported as:
Number · Proportion of participants
Proportion of Subjects Requiring an Intensification of Hypoglycemic Agent and Time to First Intensification
Proportion of participantsBexagliflozin Tablets, 20 mgPlacebo Tablets
Proportion of Subjects Requiring an Intensification of Hypoglycemic Agent and Time to First Intensification0.06 (0.05 to 0.08)0.18 (0.15 to 0.21)
Statistical analysis
  • Bexagliflozin Tablets, 20 mg vs Placebo Tablets · Regression, Logistic · p = <0.0001 (P-value is based on one sided statistical tests using a 0.025 level of significance.) · Odds ratio (or): 0.30 · 95% CI 0.22 to 0.41Odds ratio is calculated as the odds ratio of bexagliflozin over placebo.
Other pre-specifiedProportion of Subjects Requiring an Intensification of Hypoglycemic Agent and Time to First Intensification

To measure the proportion of subjects requiring an intensification of hypoglycemic agent in the bexagliflozin arm versus placebo during the entire study period

Time frame:
Duration of study (168 weeks)
Reported as:
Number · Proportion of participants
Proportion of Subjects Requiring an Intensification of Hypoglycemic Agent and Time to First Intensification
Proportion of participantsBexagliflozin Tablets, 20 mgPlacebo Tablets
Proportion of Subjects Requiring an Intensification of Hypoglycemic Agent and Time to First Intensification0.06 (0.05 to 0.08)0.18 (0.15 to 0.21)
Statistical analysis
  • Bexagliflozin Tablets, 20 mg vs Placebo Tablets · Regression, Cox · p = <0.0001 (P-value is based on one sided statistical tests using a 0.025 level of significance.) · Hazard ratio (hr): 0.41 · 95% CI 0.35 to 0.49Hazard ratio and p-value were estimated using Cox regression model for time to first event in the bexagliflozin arm vs. placebo arm during entire study.
Other pre-specifiedProportion of Subjects Requiring a Relaxation of Hypoglycemic Agent

To measure the proportion of subjects requiring a relaxation of hypoglycemic agent in the bexagliflozin arm versus placebo during 24 week period

Time frame:
24 weeks
Reported as:
Number · Proportion of participants
Proportion of Subjects Requiring a Relaxation of Hypoglycemic Agent
Proportion of participantsBexagliflozin Tablets, 20 mgPlacebo Tablets
Proportion of Subjects Requiring a Relaxation of Hypoglycemic Agent0.09 (0.08 to 0.11)0.05 (0.03 to 0.07)
Statistical analysis
  • Bexagliflozin Tablets, 20 mg vs Placebo Tablets · Regression, Logistic · p = 0.0005 (P-value is based on one sided statistical tests using a 0.025 level of significance.) · Odds ratio (or): 2.04 · 95% CI 1.33 to 3.11Odds ratio is calculated as the ratio of bexagliflozin over placebo.
Other pre-specifiedProportion of Subjects Requiring a Relaxation of Hypoglycemic Agent

To measure the proportion of subjects requiring a relaxation of hypoglycemic agent in the bexagliflozin arm versus placebo during the entire study

Time frame:
Duration of study (168 weeks)
Reported as:
Number · Proportion of participants
Proportion of Subjects Requiring a Relaxation of Hypoglycemic Agent
Proportion of participantsBexagliflozin Tablets, 20 mgPlacebo Tablets
Proportion of Subjects Requiring a Relaxation of Hypoglycemic Agent0.09 (0.08 to 0.11)0.05 (0.03 to 0.07)
Statistical analysis
  • Bexagliflozin Tablets, 20 mg vs Placebo Tablets · Regression, Cox · p = <0.0001 (P-value is based on one sided statistical tests using a 0.025 level of significance.) · Hazard ratio (hr): 1.82 · 95% CI 1.40 to 2.38Hazard ratio and p-value were estimated using Cox regression model for time to first event in the bexagliflozin arm vs. placebo arm during the entire study.
Other pre-specifiedProportion of Participants With Incidence of Hospitalization for Heart Failure

To measure the incidence of hospitalization for heart failure among all subjects and among subjects who have a history of heart failure at baseline

Time frame:
Duration of study (168 weeks)
Reported as:
Number · Proportion of participants
Proportion of Participants With Incidence of Hospitalization for Heart Failure
Proportion of participantsAll Subjects: Bexagliflozin Tablets, 20 mgAll Subjects: Placebo TabletsSubjects With HF History: Bexagliflozin Tablets, 20 mgSubjects With HF History: Placebo
Proportion of Participants With Incidence of Hospitalization for Heart Failure0.01 (0.01 to 0.02)0.02 (0.01 to 0.03)0.05 (0.03 to 0.08)0.09 (0.05 to 0.15)
Statistical analysis
  • All Subjects: Bexagliflozin Tablets, 20 mg vs All Subjects: Placebo Tablets · Regression, Logistic · p = 0.0803 (P-value is based on one sided statistical tests using a 0.025 level of significance.) · Odds ratio (or): 0.63 · 95% CI 0.33 to 1.20Odds ratio is calculated as the odds ratio of bexagliflozin over placebo.
  • Subjects With HF History: Bexagliflozin Tablets, 20 mg vs Subjects With HF History: Placebo · Regression, Logistic · p = 0.0272 (P-value is based on one sided statistical tests using a 0.025 level of significance.) · Odds ratio (or): 0.47 · 95% CI 0.22 to 1.01Odds ratio is calculated as the odds ratio of bexagliflozin over placebo.
  • All Subjects: Bexagliflozin Tablets, 20 mg vs All Subjects: Placebo Tablets · Regression, Cox · p = 0.0757 (P-value is based on one sided statistical tests using a 0.025 level of significance.) · Hazard ratio (hr): 0.63 · 95% CI 0.34 to 1.18Hazard ratio and p-value were estimated using Cox regression model for treatment comparison vs. placebo.
  • Subjects With HF History: Bexagliflozin Tablets, 20 mg vs Subjects With HF History: Placebo · Regression, Cox · p = 0.0273 (P-value is based on one sided statistical tests using a 0.025 level of significance.) · Hazard ratio (hr): 0.49 · 95% CI 0.23 to 1.01Hazard ratio and p-value were estimated using Cox regression model for treatment comparison vs. placebo.

Adverse events

Collected over Adverse event data were collected from the first dose to the last day of follow up (4 weeks after the End of Treatment visit, an average of 127 weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Bexagliflozin Tablets, 20 mg39/1,132 (3.4%)373/1,132 (33%)739/1,132 (65.3%)
Placebo Tablets26/567 (4.6%)208/567 (36.7%)386/567 (68.1%)
Most frequent serious events
Showing 10 of 361
Most frequent serious events
EventBexagliflozin Tablets, 20 mgPlacebo Tablets
Angina unstableCardiac disorders31/113219/567
Acute myocardial infarctionCardiac disorders31/113214/567
Cardiac failure congestiveCardiac disorders18/113215/567
Myocardial infarctionCardiac disorders11/113213/567
Angina pectorisCardiac disorders16/113211/567
Cardiac failureCardiac disorders21/11327/567
Coronary artery diseaseCardiac disorders21/11326/567
PneumoniaInfections and infestations11/113210/567
Atrial fibrillationCardiac disorders15/11329/567
HypoglycaemiaMetabolism and nutrition disorders14/11328/567
Most frequent other events
Showing 10 of 12
Most frequent other events
EventBexagliflozin Tablets, 20 mgPlacebo Tablets
HypoglycaemiaMetabolism and nutrition disorders475/1132246/567
Urinary tract infectionInfections and infestations128/113260/567
Upper respiratory tract infectionInfections and infestations112/113253/567
NasopharyngitisInfections and infestations96/113239/567
HyperglycaemiaMetabolism and nutrition disorders68/113241/567
NauseaGastrointestinal disorders54/113237/567
DiarrhoeaGastrointestinal disorders72/113231/567
HypertensionVascular disorders45/113236/567
BronchitisInfections and infestations52/113234/567
Back painMusculoskeletal and connective tissue disorders66/113233/567

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Bexagliflozin Tablets, 20 mgPlacebo TabletsTotal
<=18 years000
Between 18 and 65 years562276838
>=65 years571291862
Age, Continuous
Age, Continuous(years)Bexagliflozin Tablets, 20 mgPlacebo TabletsTotal
Mean64.4 ± 7.9464.6 ± 8.0164.4 ± 7.96
Sex: Female, Male
Sex: Female, Male(Participants)Bexagliflozin Tablets, 20 mgPlacebo TabletsTotal
Female341177518
Male7923901182
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Bexagliflozin Tablets, 20 mgPlacebo TabletsTotal
Hispanic or Latino16693259
Not Hispanic or Latino9674741441
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Bexagliflozin Tablets, 20 mgPlacebo TabletsTotal
American Indian or Alaska Native9854152
Asian10855163
Native Hawaiian or Other Pacific Islander202
Black or African American462874
White8794301309
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)Bexagliflozin Tablets, 20 mgPlacebo TabletsTotal
Canada672491
Netherlands361854
South Korea482674
United States397205602
Czechia11852170
Taiwan462066
Denmark171027
Poland19697293
Mexico12162183
Russia8753140
Cardiovascular Risk Groups
Cardiovascular Risk Groups(Participants)Bexagliflozin Tablets, 20 mgPlacebo TabletsTotal
Group 1: History of atherosclerotic vascular disease7033621065
Group 2: History of heart failure16680246
Group 3: Age >= 55 years with > 2 risk factors264125389
Body Weight
Body Weight(kg)Bexagliflozin Tablets, 20 mgPlacebo TabletsTotal
Mean94.59 ± 21.8792.62 ± 19.99993.94 ± 20.745

14 further baseline measures are reported on the registry.

08

Study locations

157 sites
  • Research Site 1090
    Gilbert, Arizona 85295, United States
  • Research Site 1041
    Little Rock, Arkansas 72204, United States
  • Research Site 1073
    Azusa, California 91773, United States
  • Research Site 1076
    Concord, California 94520, United States
  • Research Site 1078
    Fresno, California 93720, United States
  • Research Site 1089
    Harbor City, California 90710, United States
  • Research Site 1058
    Lincoln, California 95821, United States
  • Research Site 1051
    Los Angeles, California 90022, United States
  • Research Site 1004
    Los Angeles, California 90057, United States
  • Research Site 1068
    Montclair, California 91763, United States
  • Research Site 1077
    Orange, California 92868, United States
  • Research Site 1218
    Denver, Colorado 80209, United States
  • Research Site 1092
    Golden, Colorado 80401, United States
  • Research Site 1216
    Norwalk, Connecticut 06851, United States
  • Research Site 1083
    Newark, Delaware 19713, United States
  • Research Site 1057
    Boca Raton, Florida 33434, United States
  • Research Site 1059
    Brooksville, Florida 34601, United States
  • Research Site 1050
    Panama City, Florida 32401, United States
  • Research Site 1099
    Port Charlotte, Florida 33952, United States
  • Research Site 1066
    Tampa, Florida 33634, United States
  • Research Site 1072
    Augusta, Georgia 30909, United States
  • Research Site 1082
    Pocatello, Idaho 83201, United States
  • Research Site 1258
    Champaign, Illinois 61822, United States
  • Research Site 1043
    Anderson, Indiana 46011, United States
  • Research Site 1071
    Avon, Indiana 46123, United States
  • Research Site 1086
    Des Moines, Iowa 50314, United States
  • Research Site 1224
    Covington, Kentucky 41011, United States
  • Research Site 1228
    Annapolis, Maryland 21401, United States
  • Research Site 1221
    Baltimore, Maryland 21202, United States
  • Research Site 1079
    Hyattsville, Maryland 20782, United States
  • Research Site 1223
    Midland, Michigan 48670, United States
  • Research Site 1217
    Petoskey, Michigan 49770, United States
  • Research Site 1254
    Ypsilanti, Michigan 48197, United States
  • Research Site 1054
    Saint Louis, Missouri 63136, United States
  • Research Site 1060
    Saint Louis, Missouri 63141, United States
  • Research Site 1252
    Kalispell, Montana 59901, United States
  • Research Site 1052
    Omaha, Nebraska 68131, United States
  • Research Site 1263
    Omaha, Nebraska 68198, United States
  • Research Site 1080
    Las Vegas, Nevada 89123, United States
  • Research Site 1219
    Somerset, New Jersey 08873, United States
  • Research Site 1044
    Albuquerque, New Mexico 87102, United States
  • Research Site 1264
    Bronx, New York 10468, United States
  • Research Site 1220
    Saratoga Springs, New York 12866, United States
  • Research Site 1049
    West Seneca, New York 14224, United States
  • Research Site 1085
    Chapel Hill, North Carolina 27517, United States
  • Research Site 1074
    Charlotte, North Carolina 28204, United States
  • Research Site 1056
    Morehead City, North Carolina 28557, United States
  • Research Site 1229
    Wilmington, North Carolina 28401, United States
  • Research Site 1064
    Winston-Salem, North Carolina 27103, United States
  • Research Site 1075
    Fargo, North Dakota 58103, United States
  • Research Site 1266
    Lindsay, Oklahoma 73052, United States
  • Research Site 1055
    Oklahoma City, Oklahoma 73119, United States
  • Research Site 1265
    Oklahoma City, Oklahoma 73134, United States
  • Research Site 1046
    Oklahoma City, Oklahoma 73135, United States
  • Research Site 1260
    Lancaster, Pennsylvania 17601, United States
  • Research Site 1042
    Cumberland, Rhode Island 02864, United States
  • Research Site 1225
    Austin, Texas 78758, United States
  • Research Site 1259
    Dallas, Texas 75235, United States
  • Research Site 1048
    Kingwood, Texas 77339, United States
  • Research Site 1070
    Lampasas, Texas 76550, United States
  • Research Site 1222
    Lewisville, Texas 75067, United States
  • Research Site 1081
    North Richland Hills, Texas 76180, United States
  • Research Site 1226
    San Antonio, Texas 78212, United States
  • Research Site 1053
    San Antonio, Texas 78218, United States
  • Research Site 1063
    Salt Lake City, Utah 84124, United States
  • Research Site 1230
    Salem, Virginia 24153, United States
  • Research Site 5013
    Vancouver, British Columbia V5Z1M9, Canada
  • Research Site 5015
    Cambridge, Ontario N1R 6V6, Canada
  • Research Site 5012
    Hamilton, Ontario L8L5G8, Canada
  • Research Site 5023
    London, Ontario N6A 4V2, Canada
  • Research Site 5016
    Peterborough, Ontario K9J 0B2, Canada
  • Research Site 5005
    Sudbury, Ontario P3C 5K7, Canada
  • Research Site 5022
    Toronto, Ontario M5B 1W8, Canada
  • Research Site 5014
    Toronto, Ontario M5G 1XS, Canada
  • Research Site 5008
    Gatineau, Quebec J8Y 6S8, Canada
  • Research Site 5007
    St-Charles-Borromee, Quebec J6E 6J2, Canada
  • Research Site 5009
    St. Georges, Quebec G5Y4T8, Canada
  • Research Site 5006
    Quebec, G1V 4G5, Canada
  • Research Site 3116
    Benesov, 256 01, Czechia
  • Research Site 3106
    Brandys nad Labem, 250 01, Czechia
  • Research Site 3107
    Brno, 60200, Czechia
  • Research Site 3118
    Brno, 639 00, Czechia
  • Research Site 3109
    Cesky Krumlov, 381 01, Czechia
  • Research Site 3114
    Havirov, 736 01, Czechia
  • Research Site 3103
    Hradec Kralove, 50005, Czechia
  • Research Site 3110
    Krnov, 794 01, Czechia
  • Research Site 3102
    Kromeriz, 767 01, Czechia
  • Research Site 3105
    Marianske Lazne, 353 01, Czechia
  • Research Site 3113
    Plzen, 326 00, Czechia
  • Research Site 3104
    Praha, 128 08, Czechia
  • Research Site 3111
    Praha, 149 00, Czechia
  • Research Site 3112
    Praha, 181 00, Czechia
  • Research Site 3115
    Uherske Hradiste, 686 68, Czechia
  • Research Site 6104
    Copenhagen, 2100, Denmark
  • Research Site 6103
    Copenhagen, 2300S, Denmark
  • Research Site 6105
    Copenhagen, 2400, Denmark
  • Research Site 7007
    Chuncheon, Gangwon-Do 200-722, Korea, Republic of
  • Research Site 7001
    Wonju, Gangwon-Do 220-701, Korea, Republic of
  • Research Site 7004
    Anyang, Gyeonggi-do 431-070, Korea, Republic of
  • Research Site 7005
    Guri, Gyeonggi-do 471-701, Korea, Republic of

Showing the first 100 of 157 sites across 10 countries. Choose a country and city above to see the rest.

09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2015 to primary completion in Aug 2018, 34 months.

Results were first posted in Jul 2021, 2 years 11 months after primary completion.

Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 34 months is above that.

Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 22, 2015
First posted
Sep 23, 2015
StartActual
Oct 2015
Primary completionActual
Aug 2018
CompletionActual
Oct 23, 2019
Results first posted
Jul 7, 2021
Last update
Jul 14, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 14, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02558296
Lead sponsor
Theracos
Responsible party
Sponsor
First posted
Sep 23, 2015
Start date
Oct 2015
Primary completion
Aug 2018
Completion
Oct 23, 2019
Results posted
Jul 7, 2021
Last update
Jul 14, 2021

Study contacts

J. Paul Lock, MD
study director · Theracos

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bexagliflozin

Start the discussion